REFERENCES
1. Aldroubi BG, Najjar JA, Youssef TS, et al. Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1. Metab Target Organ Damage. 2024;4:34.
2. Chandrasekaran P, Weiskirchen R. Diabetes mellitus and heart disease. Metab Target Organ Damage. 2024;4:18.
3. Lonardo A, Ballestri S, Baffy G, Weiskirchen R. Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease. Metab Target Organ Damage. 2024;4:41.
4. Bourebaba N, Marycz K. Hepatic stellate cells role in the course of metabolic disorders development - a molecular overview. Pharmacol Res. 2021;170:105739.
5. Cai CX, Buddha H, Castelino-Prabhu S, et al. Activation of insulin-PI3K/Akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci. 2017;62:968-78.
6. Kaji K, Yoshiji H, Ikenaka Y, et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol. 2014;49:481-91.
7. Kaya D, Kaji K, Tsuji Y, et al. TGR5 activation modulates an inhibitory effect on liver fibrosis development mediated by anagliptin in diabetic rats. Cells. 2019;8:1153.
8. Zhang F, Zhang Z, Kong D, et al. Tetramethylpyrazine reduces glucose and insulin-induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated PI3K/AKT and ERK pathways. Mol Cell Endocrinol. 2014;382:197-204.
9. Creeden JF, Kipp ZA, Xu M, et al. Hepatic kinome atlas: an in-depth identification of kinase pathways in liver fibrosis of humans and rodents. Hepatology. 2022;76:1376-88.
10. Kitsios K, Trakatelli CM, Antza C, Triantafyllou A, Sarigianni M, Kotsis V. Treatment of metabolic (dysfunction)-associated fatty liver disease: evidence from randomized controlled trials-a short review. Metab Syndr Relat Disord. 2024;22:703-8.
11. Jiang Y, Wu L, Zhu X, Bian H, Gao X, Xia M. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics. Lipids Health Dis. 2024;23:95.
12. Dodig M, Li M, Dasarathy S, et al. Insulin increases type I collagen synthesis in hepatic stellate cells via α5β1 integrin. Metab Target Organ Damage. 2024;4:49.
13. Poy MN, Yang Y, Rezaei K, et al. CEACAM1 regulates insulin clearance in liver. Nat Genet. 2002;30:270-6.
14. Park SY, Cho YR, Kim HJ, et al. Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. Am J Physiol Endocrinol Metab. 2006;291:E517-24.
15. Walsh A, Ito Y, Breslow JL. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J Biol Chem. 1989;264:6488-94.
16. Nishimichi N, Tsujino K, Kanno K, et al. Induced hepatic stellate cell integrin, α8β1, enhances cellular contractility and TGFβ activity in liver fibrosis. J Pathol. 2021;253:366-3.
18. Weiskirchen R, Tacke F. Liver fibrosis: from pathogenesis to novel therapies. Dig Dis. 2016;34:410-22.
19. Jamalinia M, Lonardo A, Weiskirchen R. Sex and gender differences in liver fibrosis: pathomechanisms and clinical outcomes. Fibrosis. 2024;2:10006.
20. Turaga RC, Satyanarayana G, Sharma M, et al. Targeting integrin αvβ3 by a rationally designed protein for chronic liver disease treatment. Commun Biol. 2021;4:1087.
21. Yokosaki Y, Nishimichi N. New therapeutic targets for hepatic fibrosis in the integrin family, α8β1 and α11β1, induced specifically on activated stellate cells. Int J Mol Sci. 2021;22:12794.
22. Ulmasov B, Noritake H, Carmichael P, Oshima K, Griggs DW, Neuschwander-Tetri BA. An inhibitor of arginine-glycine-aspartate-binding integrins reverses fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatol Commun. 2018;3:246-61.
